By Joana Vindeirinho, PhD on 01/31/2023
Spark Therapeutics and Neurochase have joined forces to develop Neurochase’s proprietary delivery technology for gene therapies that target neurodegenerative diseases, such as Huntington’s disease. The technology, called Convection Enhanced Delivery (CED), allows for a controlled delivery of gene and other therapies directly into specific brain regions with the aim of increasing a therapy’s effectiveness and avoiding […]
The post Spark, Neurochase Collaborate on Brain Delivery Technology appeared first on Huntington's Disease News.
|